TacticScaleWhat United Therapeutics Does & How It Makes Money (UTHR)
Updated October 2026 · reflects United Therapeutics's latest reported financials
Biotech company making treatments for pulmonary arterial hypertension and organ transplants. It earns revenue mainly by selling prescription PAH drugs built on treprostinil (Tyvaso, Remodulin, Orenitram) plus Adcirca and the cancer antibody Unituxin.
How United Therapeutics makes money
It earns revenue mainly by selling prescription PAH drugs built on treprostinil (Tyvaso, Remodulin, Orenitram) plus Adcirca and the cancer antibody Unituxin. It also sells delivery devices like the Remunity Pump and works with partners such as MannKind and DEKA on drug delivery technology.
What United Therapeutics does
United Therapeutics, founded in 1996 and based in Silver Spring, Maryland, is a specialty biotech company focused on chronic and life-threatening diseases. Its main business is pulmonary arterial hypertension. It sells several forms of treprostinil: Tyvaso as an inhaled dry powder or a nebulized solution, Remodulin as an injection, and Orenitram as an oral tablet. It also sells the oral PDE-5 inhibitor Adcirca, the Remunity Pump for giving Remodulin, and Unituxin, an antibody for high-risk neuroblastoma. It works with partners including MannKind on the Tyvaso DPI inhaler and DEKA on under-the-skin delivery systems. Its pipeline includes Ralinepag and the RemunityPRO Pump for PAH, and Nebulized Tyvaso for idiopathic pulmonary fibrosis. Its longer-term bet is on organ supply. Those projects include EVLP/CLES lung-transplant technology, gene-edited pig kidneys and hearts for transplant into humans (UKidney, UHeart, UThymoKidney), and regenerative medicine organs such as ULobe, ULung, miroliver and mirokidney. They are still in early development.
Products & services
- Tyvaso DPI / Nebulized Tyvaso
- Remodulin (treprostinil) injection
- Orenitram
- Adcirca
- Unituxin (dinutuximab)
- Remunity Pump
What is United Therapeutics worth?
On an owner-earnings DCF, United Therapeutics's most-likely value is about $636 versus a recent price near $549 (16% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$284) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Liquidia (LQDA) · PTC Therapeutics (PTCT) · Protagonist Therapeutics (PTGX) · Upstream Bio (UPB) · Amgen (AMGN)